SPOTLIGHT: Targeted Genetics hits back against trial report


Targeted Genetics went on the attack after The Washington Post raised serious criticisms of a gene therapy trial that was suspended after the death of a volunteer. But Wired also notes that the company's response avoids many of the most serious criticisms leveled in the report. Report

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.